- Stocks
- Healthcare
- NASDAQ: IPSC

Price (delayed)

$2.475

Market cap

$205.05M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.21

Enterprise value

$200.51M

The quick ratio has increased by 32% year-on-year and by 23% since the previous quarter

The debt has declined by 14% year-on-year and by 5% since the previous quarter

Century Therapeutics's net income has decreased by 7% YoY but it has increased by 2.3% from the previous quarter

The EPS has increased by 3.9% since the previous quarter but it has declined by 2.8% year-on-year

Century Therapeutics's gross profit has plunged by 77% YoY and by 39% from the previous quarter

The revenue has dropped by 77% year-on-year and by 39% since the previous quarter

What are the main financial stats of IPSC

Market
Valuations
Earnings

Shares outstanding

82.85M

Market cap

$205.05M

Enterprise value

$200.51M

Price to earnings (P/E)

N/A

Price to book (P/B)

0.9

Price to sales (P/S)

112.54

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

146.36

Revenue

$1.37M

EBIT

-$132.66M

EBITDA

-$118.22M

Free cash flow

-$98.66M

Per share
Balance sheet
Liquidity

EPS

-$2.21

Free cash flow per share

-$1.58

Book value per share

$2.74

Revenue per share

$0.02

TBVPS

$5.59

Total assets

$348.51M

Total liabilities

$170.62M

Debt

$44.25M

Equity

$177.88M

Working capital

$183.75M

Debt to equity

0.25

Current ratio

12.44

Quick ratio

12.08

Net debt/EBITDA

0.04

Margins
Efficiency
Dividend

EBITDA margin

-8,628.8%

Gross margin

100%

Net margin

-9,742.4%

Operating margin

-10,640.4%

Return on assets

-35%

Return on equity

-64.4%

Return on invested capital

-37.7%

Return on capital employed

-39.9%

Return on sales

-9,683.3%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Century Therapeutics stock price performed over time

Intraday

1.85%

1 week

-24.77%

1 month

-13.46%

1 year

-20.67%

YTD

-25.45%

QTD

-2.94%

How have Century Therapeutics's revenue and profit performed over time

Revenue

$1.37M

Gross profit

$1.37M

Operating income

-$145.77M

Net income

-$133.47M

Gross margin

100%

Net margin

-9,742.4%

Century Therapeutics's gross profit has plunged by 77% YoY and by 39% from the previous quarter

The revenue has dropped by 77% year-on-year and by 39% since the previous quarter

Century Therapeutics's operating margin has shrunk by 62% QoQ

The net margin has dropped by 59% since the previous quarter

What is Century Therapeutics's growth rate over time

What is Century Therapeutics stock price valuation

P/E

N/A

P/B

0.9

P/S

112.54

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

146.36

The EPS has increased by 3.9% since the previous quarter but it has declined by 2.8% year-on-year

The equity has declined by 36% year-on-year and by 3.7% since the previous quarter

IPSC's price to book (P/B) is 11% lower than its last 4 quarters average of 1.0

The revenue has dropped by 77% year-on-year and by 39% since the previous quarter

The price to sales (P/S) is 21% higher than the last 4 quarters average of 91.7

How efficient is Century Therapeutics business performance

Century Therapeutics's ROE has plunged by 64% YoY and by 9% from the previous quarter

The return on sales has dropped by 61% since the previous quarter

Century Therapeutics's return on assets has decreased by 39% YoY and by 4.5% QoQ

The ROIC has contracted by 29% YoY and by 3% from the previous quarter

What is IPSC's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for IPSC.

How did Century Therapeutics financials performed over time

Century Therapeutics's total assets is 104% higher than its total liabilities

The current ratio has grown by 35% YoY and by 25% from the previous quarter

The quick ratio has increased by 32% year-on-year and by 23% since the previous quarter

The debt is 75% smaller than the equity

The equity has declined by 36% year-on-year and by 3.7% since the previous quarter

IPSC's debt to equity is up by 32% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.